Subscribe to RSS
Excellent Radiological Response with Modern Contemporary Proton Beam Therapy in Favorable Molecular Low-Intermediate Grade Oligodendroglioma: A Report of Two Cases
Radiotherapy (RT) has been a long-standing treatment option for low-grade glioma. Improvements in tumor control and reduced radiation-related toxicity can be attributed to advances in neuroimaging as well as RT treatment planning and delivery techniques. The molecular markers such as isocitrate dehydrogenase and lpl9q play a key role in determining which patients will benefit most from combined radiation and systemic therapy. We hereby report two cases of favorable molecular low-intermediate grade oligodendroglioma treated with modern proton pencil-beam therapy under high-precision image guidance showing excellent radiological response that is usually not seen with conventional photon radiation.
28 May 2021 (online)
© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131 (06) 803-820
- 2 Pignatti F, van den Bent M, Curran D. et al. European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group, European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002; 20 (08) 2076-2084
- 3 Santosh V, Sravya P, Gupta T. et al. ISNO consensus guidelines for practical adaptation of the WHO 2016 classification of adult diffuse gliomas. Neurol India 2019; 67 (01) 173-182
- 4 Armstrong GT, Conklin HM, Huang S. et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro-oncol 2011; 13 (02) 223-234
- 5 Gondi V, Hermann BP, Mehta MP, Tomé WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys 2012; 83 (04) e487-e493
- 6 Hauswald H, Rieken S, Ecker S. et al. First experiences in treatment of low-grade glioma grade I and II with proton therapy. Radiat Oncol 2012; 7: 189
- 7 Buckner JC, Shaw EG, Pugh SL. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade Glioma. N Engl J Med 2016; 374 (14) 1344-1355
- 8 van den Bent MJ, Baumert B, Erridge SC. et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 2017; 390 (10/103) 1645-1653
- 9 Thurin E, Nyström PW, Smits A. et al. Proton therapy for low-grade gliomas in adults: a systematic review. Clin Neurol Neurosurg 2018; 174: 233-238
- 10 Grosshans DR, Mohan R, Gondi V, Shih HA, Mahajan A, Brown PD. The role of image-guided intensity modulated proton therapy in glioma. Neuro-oncol 2017; 19 (Suppl. 02) ii30-ii37